Actively Recruiting
Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models
Led by Chen Xiaoping · Updated on 2024-06-17
30
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected. Local and systemic therapy are the main treatments for unresectable HCC. Two recent trials of HAIC combined with PD-1 monoclonal antibody and targeted therapy reported objective response rates (ORR) as high as 43.3% to 77.1%.
CONDITIONS
Official Title
Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- No previous local or systemic treatment for hepatocellular carcinoma
- Child-Pugh liver function score of 7 or less
- ECOG performance status 0 to 1
- No serious organic diseases of the heart, lungs, brain, kidneys, or similar
- Tumor determined to be technically unresectable by enhanced MRI
- Hepatocellular carcinoma confirmed by biopsy
- Screening by multimodal deep learning model suggests benefit from HAIC combined with lenvatinib and PD-1 inhibitors
You will not qualify if you...
- Pregnant or breastfeeding women
- Conditions interfering with absorption, distribution, metabolism, or clearance of study drugs (e.g., severe vomiting, chronic diarrhea, intestinal blockage, impaired absorption)
- History of gastrointestinal bleeding within 4 weeks or predisposition to bleeding not treated
- Active infection
- Other significant clinical or lab abnormalities affecting safety evaluation
- Inability to follow study treatment or follow-up schedule
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
Research Team
W
WanGuang Zhang
CONTACT
X
xiaoping Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here